Medivir AB (publ) (STO: MVIR)

Market Cap	319.68M
Revenue (ttm)	7.03M
Net Income (ttm)	-116.92M
Shares Out	112.17M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,318
Average Volume	119,362
Open	2.850
Previous Close	2.890
Day's Range	2.820 - 2.870
52-Week Range	2.330 - 4.200
Beta	-0.16
RSI	47.75
Earnings Date	Feb 18, 2025

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2023, Medivir AB's revenue was 7.63 million, an increase of 73.16% compared to the previous year's 4.41 million. Losses were -89.32 million, 0.63% more than in 2022.